• Explore /
  • Poster
  • / Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Abstract Video & Slides Poster

Authors

null

Guy Heinrich Maria Jerusalem

Centre Hospitalier Universitaire du Sart Tilman Liège and Liège University, Liège, Belgium

Guy Heinrich Maria Jerusalem , Yeon Hee Park , Toshinari Yamashita , Sara A. Hurvitz , Shanu Modi , Fabrice Andre , Ian E. Krop , Xavier Gonzalez , Peter S. Hall , Benoit You , Cristina Saura , Sung-Bae Kim , Cynthia R. C. Osborne , Yasuaki Sagara , Eriko Tokunaga , Yali Liu , Jillian Cathcart , Caleb C. Lee , Christophe Perrin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT03248492

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 526)

DOI

10.1200/JCO.2021.39.15_suppl.526

Abstract #

526

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ian E. Krop

First Author: Ian E. Krop

First Author: Jose Baselga

First Author: Hossein Borghaei